Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The application window for the 2025 National Genomic Test Directory is open in England

The National Genomic Test Directory lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. It is updated annually following a structured, evidence-based process defined by the NHS England in the specific policy. Anyone can submit an application to update the Test Directory; this may be to consider new test targets, clinical indications, and/or changes to existing tests on the Test Directory.

The scheduled timelines and activities for the next update cycle include the following:

  • The application window closes ​on April 1, 2024;
  • Applications reviewed by NHS England and Test Evaluation Working Groups​;
  • Updated Test Directory published, and Genomic Laboratory Hubs ​implemented changes on April 1, 2025.

Application forms and further guidance for applicants are available in the Documentation section (bottom of the webpage). Relevant application forms should be submitted via email to england.testevaluation@nhs.net.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.